Date: 2015-05-01
Type of information: Collaboration agreement
Compound: macrocylic/constrained peptides
Company: Merck&Co (USA - NJ) PeptiDream (Japan)
Therapeutic area: undisclosed
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On May 1, 2015, PeptiDream, a public Tokyo-based biopharmaceutical company, announced a multi-target discovery and optimization collaboration with Merck & Co, through a subsidiary. Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocylic/constrained peptides against multiple targets of interest selected by Merck & Co. Inc. Merck & Co. Inc. will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration and retains an option to nonexclusively license the PDPS technology at a future date.
Financial terms: PeptiDream will receive an undisclosed upfront payment, research funding and will be eligible for payments associated with the achievement of certain preclinical and clinical development milestones. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.
Latest news:
